Indrayani Biotech Intrinsic Value
INDRANIB Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹4.32 | ₹3.46 - ₹5.18 | -61.4% | EPS: ₹0.36, Sector P/E: 12x |
| Book Value Method | asset | ₹15.87 | ₹14.28 - ₹17.46 | +41.8% | Book Value/Share: ₹15.87, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹22.38 | ₹20.14 - ₹24.62 | +100.0% | Revenue/Share: ₹33.04, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹20.85 | ₹18.77 - ₹22.94 | +86.3% | EBITDA: ₹16.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹27.97 | ₹22.38 - ₹33.56 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹3.36 | ₹3.02 - ₹3.70 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹3.36 | ₹3.02 - ₹3.70 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹8.70 | ₹7.83 - ₹9.57 | -22.3% | ROE: 5.5%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹11.34 | ₹10.21 - ₹12.47 | +1.3% | EPS: ₹0.36, BVPS: ₹15.87 |
Want to compare with current market value? Check INDRANIB share price latest .
Valuation Comparison Chart
INDRANIB Intrinsic Value Analysis
What is the intrinsic value of INDRANIB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Indrayani Biotech (INDRANIB) is ₹11.34 (median value). With the current market price of ₹11.19, this represents a +1.3% variance from our estimated fair value.
The valuation range spans from ₹3.36 to ₹27.97, indicating ₹3.36 - ₹27.97.
Is INDRANIB undervalued or overvalued?
Based on our multi-method analysis, Indrayani Biotech (INDRANIB) appears to be trading near calculated value by approximately 1.3%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.70 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 3.67 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 5.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.57x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Indrayani Biotech
Additional stock information and data for INDRANIB
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2024 | ₹-30 Cr | ₹-38 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹16 Cr | ₹-8 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹4 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2020 | ₹6 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |